Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past 7 days
Any time
Past hour
Past 24 hours
Past 30 days
Most recent
Best match
4d
Neumora Therapeutics: A Story Of A Class II Biotech
Neumora's lead asset, Navacaprant, shows weak efficacy in phase 2 trial. Read why we are not optimistic about NMRA's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Liberty win first WNBA title
Advance to World Series
Reopening w/ safety features
Reaches tentative union deal
Boat rider arrested in FL
Trump's Pennsylvania rally
Opens up on Russian camp
Postpones US tour
Bladder cancer drug pulled
New Mexico flash flooding
Baldwin returns to 'SNL'
NYC Halloween dog parade
Philip Zimbardo dies at 91
Rock & Roll HOF '24 class
Frozen waffles recalled
Orionids meteor shower
Ferry dock collapses in GA
US probing documents leak
US deficit reaches $1.8T
ISR strikes northern Gaza
Ex-MN congressman dies
Antitrust ruling delayed
Launches OneWeb mission
Opioid suits settlement deal
CVS workers strike
Urges support for Ukraine
Challenges military listing
Oscar makes landfall
G7 ministers back Ukraine
Probes near miss in Austin
Oakland fire burns homes
Feedback